A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

April 22, 2025

Study Completion Date

June 30, 2026

Conditions
NAFLDNASH
Interventions
DRUG

DD01

Dual GLP-1 and glucagon receptor agonist

DRUG

Placebo

Placebo matching DD01

Trial Locations (12)

64131

Summit Research Site, Kansas City

71201

Summit Research Site, Monroe

71291

Summit Research Site, West Monroe

77401

Summit Research Site, Bellaire

78222

Summit Research Site, San Antonio

78229

Summit Research Site, San Antonio

78404

Summit Research Site, Corpus Christi

78520

Summit Research Site, Brownsville

78539

Summit Research Site, Edinburg

78626

Summit Research Site, Georgetown

78757

Summit Research Site, Austin

92751

Summit Research Site, Maitland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neuraly, Inc.

INDUSTRY

NCT06410924 - A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH | Biotech Hunter | Biotech Hunter